cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.7334708.v1
title: Assessment of the Severity of Paravalvular Regurgitation and its Role on Survival After Transcather Aortic Valve Replacement

description: <b>Background</b>: To evaluate the impact of various measurements of paravalvular regurgitation (PVR) on survival after transcatheter aortic valve replacement (TAVR). PVR can be difficult to grade and both its incidence and impact on survival may be decreasing as TAVR evolves. <b>Methods</b>: This retrospective study included 911 patients undergoing TAVR in two institutions. PVR was graded according to the 3-grade scheme proposed by the guidelines (PVR grade), and subsequently grade 2 and 3, and grade 0 and 1 were lumped together. PVR was also graded as a composite score (PVR score), based on 6 commonly used metrics. PVR grade, PVR score and its 6 individual components were tested against the risk of both 1-year and longer term mortality after TAVR. <b>Results</b>: Patients with moderate/severe PVR had a higher STS score, higher levels of serum creatinine and larger left atria compared to patients with none/mild PVR. Moderate/severe PVR was more frequent with self-expandable and larger valves. After adjusting for ACC TAVR risk score, neither PVR grade, PVR score nor its 6 components were associated with an increased risk of mortality at 1-year (severe PVR adjusted HR: 0.75, 95% Confidence Interval [CI]: 0.19, 3.01, p = 0.50). However, intervention for clinically severe PVR increased the risk of mortality by more than 7-fold (Adjusted HR: 7.6, 95% CI: 2.4, 23.5, p <b>Conclusions</b>: In the contemporary era, moderate-severe PVR is uncommon. However, re-intervention for PVR portends a poor prognosis. This highlights the crucial importance of clinical judgment over imaging alone.
DOI: 10.6084/m9.figshare.7464383.v1
title: Device Closure of Patent Foramen Ovale– Is it Time to Update Guidelines?

description: <b>Background</b>: The current American Association of Neurology guidelines do not recommend patent foramen ovale (PFO) closure for prevention of cryptogenic strokes however recent findings from randomized control trials (RCT) challenged this recommendation. We performed a comprehensive analysis of RCTs available to date to compare PFO closure to medical therapy in patients with cryptogenic stroke. <b>Methods</b>: Five databases were analyzed including EMBASE, PubMed, Cochrane, Scopus and Web-of-Science from January 2000 to September 2018. We included RCTs comparing device closure of PFO versus medical therapy in patients with cryptogenic stroke. Heterogeneity was determined using Cochrane’s Q statistics. A random effects model was used. <b>Results</b>: Six randomized controlled trials and 3,560 patients were included in the analysis. Mean follow-up was 47±19 months. Device closure was associated with a 42% reduction in recurrent embolic strokes when compared to medical therapy (risk ratio (RR): 0.58, 95% CI: 0.39-0.88, P=0.009). This occurred despite atrial fibrillation occurring at a higher rate with device closure when compared to medical therapy (RR: 4.75, 95% CI: 2.35-9.60, P&lt;0.001). There was no difference between the two groups with respect to all-cause mortality, transient ischemic attacks, major bleeding or adverse events. <b>Conclusions</b>: PFO device closure in appropriately selected patients with cryptogenic stroke is associated with a significant reduction in the risk of recurrent ischemic stroke. The increased incidence of atrial fibrillation associated with device closure appears to be transient. Long term monitoring may be essential.
DOI: 10.6084/m9.figshare.13641106
title: What Is the Role of Cardiac Magnetic Resonance Imaging in Transcatheter Management of Aortic Valve Stenosis?

description: Transcatheter aortic valve replacement (TAVR) has changed the management paradigm of severe aortic stenosis. Cardiac magnetic resonance (CMR) has an emerging role in the evaluation of aortic stenosis. MRI provides excellent tissue characterization, endocardial definition, and is considered the gold standard for the assessment of left and right ventricular volumes, remodeling, mass, and chamber function. In addition, CMR is free from ionizing radiation, noninvasive, and an iodine-contrast sparing modality. CMR has a role in the assessment of annular dimensions, especially in individuals in whom computed tomography is contraindicated. This review discusses the contemporary role of CMR in patients with aortic stenosis, particularly in those being considered for TAVR.
DOI: 10.6084/m9.figshare.6991265
title: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion

description: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion
DOI: 10.6084/m9.figshare.6991265.v2
title: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion

description: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion
DOI: 10.6084/m9.figshare.7221605.v2
title: Percutaneous Management of Acquired Right Ventricular Outflow Tract Obstruction due to Giant Coronary Vein Graft Aneurysm

description: Percutaneous Management of Acquired Right Ventricular Outflow Tract Obstruction due to Giant Coronary Vein Graft Aneurysm
DOI: 10.6084/m9.figshare.6991265.v1
title: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion

description: Unexpected Murmur after Percutaneous Left Atrial Appendage Occlusion
DOI: 10.6084/m9.figshare.13641106.v2
title: What Is the Role of Cardiac Magnetic Resonance Imaging in Transcatheter Management of Aortic Valve Stenosis?

description: Transcatheter aortic valve replacement (TAVR) has changed the management paradigm of severe aortic stenosis. Cardiac magnetic resonance (CMR) has an emerging role in the evaluation of aortic stenosis. MRI provides excellent tissue characterization, endocardial definition, and is considered the gold standard for the assessment of left and right ventricular volumes, remodeling, mass, and chamber function. In addition, CMR is free from ionizing radiation, noninvasive, and an iodine-contrast sparing modality. CMR has a role in the assessment of annular dimensions, especially in individuals in whom computed tomography is contraindicated. This review discusses the contemporary role of CMR in patients with aortic stenosis, particularly in those being considered for TAVR.
DOI: 10.6084/m9.figshare.13641106.v1
title: What is the Role of Cardiac Magnetic Resonance Imaging in Transcatheter Management of Aortic Valve Stenosis?

description: Transcatheter aortic valve replacement (TAVR) has changed the management paradigm of severe aortic stenosis. Cardiac magnetic resonance (CMR) has an emerging role in the evaluation of aortic stenosis. MRI provides excellent tissue characterization, endocardial definition, and is considered the gold standard for the assessment of left and right ventricular volumes, remodeling, mass and chamber function. In addition, CMR is free from ionizing radiation, noninvasive, and iodine-contrast sparing modality. CMR has a role in the assessment of annular dimensions, especially in individuals in whom computed tomography is contraindicated. This review discusses the contemporary role of CMR in patients with aortic stenosis, particularly in those being considered for TAVR.
DOI: 10.6084/m9.figshare.7221605.v1
title: Percutaneous management of acquired right ventricular outflow tract obstruction due to giant coronary vein graft aneurysm

description: Percutaneous management of acquired right ventricular outflow tract obstruction due to giant coronary vein graft aneurysm
DOI: 10.6084/m9.figshare.8223854
title: Edge-to-Edge Repair of the Mitral Valve with the Mitraclip System: Evolution of Leaflet Grasping Technology

description: Edge-to-Edge Repair of the Mitral Valve with the Mitraclip System: Evolution of Leaflet Grasping Technology
DOI: 10.6084/m9.figshare.8223854.v1
title: Edge-to-Edge Repair of the Mitral Valve with the Mitraclip System: Evolution of Leaflet Grasping Technology

description: Edge-to-Edge Repair of the Mitral Valve with the Mitraclip System: Evolution of Leaflet Grasping Technology
DOI: 10.6084/m9.figshare.8026544.v1
title: Association and Prognostic Implication of C-Reactive Protein with Risk of 1-Year Death or Disabling Stroke After Transcatheter Aortic Valve Replacement

description: <b>Background</b><b>:</b> Recent data suggest that serum biomarkers may predict worse outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). We examined the association and predictive value of preprocedural levels of C-reactive protein (CRP) with clinical outcomes after TAVR. <b>Methods</b><b>:</b> We evaluated 243 patients who had undergone successful TAVR and had a valid measurement of baseline CRP level between March 2010 and February 2017. The primary endpoint was the composite of death from any cause or disabling stroke at 12 months. <b>Results</b><b>:</b> During follow-up (median, 13.7 months), primary outcome events occurred in 18 patients (8.2%), including 14 deaths (6.7%) and 5 disabling strokes (2.1%). Patients with high serum levels of CRP (≥3.0 mg/L) had a significantly higher 1-year rate of death or disabling stroke compared to those with normal CRP levels (16.7% vs. 5.5%, <i>P</i> = 0.009). In the multivariate Cox-proportional hazard model, an elevated level of CRP was identified as an independent predictor of 1-year death or disabling stroke (hazard ratio, 2.84; 95% confidence interval, 1.10–7.34; <i>P</i> = 0.03). After the addition of information about CRP concentration to the Society of Thoracic Surgeons (STS) score model, the C-index for the prediction of death or disabling stroke substantially increased from 0.655 to 0.710, and a continuous net reclassification improvement of 0.529 (0.054–1.004) was noted. And there was no significant relationship between the primary outcome and other biomarkers, included B-type natriuretic peptide (BNP) and troponin I, in our study. <b>Conclusions</b><b>:</b> In patients undergoing TAVR, elevated CRP levels were significantly associated with an increased risk of death or disabling stroke and also augmented event prediction, suggesting that CRP could be used as biomarker into a risk prediction model for TAVR.
DOI: 10.6084/m9.figshare.8118704.v3
title: Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting with or without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial

description: <b>Background:</b> This study examined the impact of mitral valve repair (MVRe) on survival of patients with moderate or severe (≥2+) MR and ischemic cardiomyopathy randomized to coronary artery bypass grafting (CABG) versus CABG+surgical ventricular reconstruction (SVR) in the STICH trial. <b>Methods:</b> Among patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG or CABG+SVR, the impact of MVRe on mortality between the two treatment arms was compared. <b>Results:</b> Among 867 patients with assessment of baseline MR severity, 211 had moderate or severe MR. After excluding 7 patients who underwent mitral valve replacement, 50, 44, 62, and 48 patients underwent CABG, CABG+MVRe, CABG+SVR, and CABG+SVR+MVRe, respectively. Four-year mortality rates were lower following CABG+MVRe than CABG alone (16% vs. 55%; adjusted hazard ratio [HR] 0.30; 95% CI 0.13–0.71). In contrast, the CABG+SVR+MVRe and CABG+SVR groups had similar 4-year mortality of 39% vs. 39% (adjusted HR 0.88; 95% CI 0.46–1.70). MVRe had a more favorable effect on survival in patients undergoing CABG alone compared to CABG+SVR (<i>p</i> = 0.013). Baseline MR severity was similar between patients that received CABG+MVRe and those that underwent CABG+SVR+MVRe. A larger proportion of patients demonstrated a reduction in MR between 4 and 24 months after CABG+MVRe compared to CABG+SVR+MVRe (50.0% versus 25.0%, <i>p</i> = 0.023). <b>Conclusion:</b> In patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG, MVRe appears to have a favorable effect on survival. The addition of SVR to CABG may attenuate the anticipated benefits of MVRe by limiting the long-term reduction of MR with MVRe.
DOI: 10.6084/m9.figshare.8141765
title: Successful MitraClip XTR for Torrential Mitral Regurgitation Secondary to Papillary Muscle Rupture as a Complication of Acute Myocardial Infarction

description: Successful MitraClip XTR for Torrential Mitral Regurgitation Secondary to Papillary Muscle Rupture as a Complication of Acute Myocardial Infarction
DOI: 10.6084/m9.figshare.8141765.v1
title: Successful MitraClip XTR for Torrential Mitral Regurgitation Secondary to Papillary Muscle Rupture as a Complication of Acute Myocardial Infarction

description: Successful MitraClip XTR for Torrential Mitral Regurgitation Secondary to Papillary Muscle Rupture as a Complication of Acute Myocardial Infarction
DOI: 10.6084/m9.figshare.8026544
title: Association and Prognostic Implication of C-Reactive Protein with Risk of 1-Year Death or Disabling Stroke After Transcatheter Aortic Valve Replacement

description: <b>Background</b><b>:</b> Recent data suggest that serum biomarkers may predict worse outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). We examined the association and predictive value of preprocedural levels of C-reactive protein (CRP) with clinical outcomes after TAVR. <b>Methods</b><b>:</b> We evaluated 243 patients who had undergone successful TAVR and had a valid measurement of baseline CRP level between March 2010 and February 2017. The primary endpoint was the composite of death from any cause or disabling stroke at 12 months. <b>Results</b><b>:</b> During follow-up (median, 13.7 months), primary outcome events occurred in 18 patients (8.2%), including 14 deaths (6.7%) and 5 disabling strokes (2.1%). Patients with high serum levels of CRP (≥3.0 mg/L) had a significantly higher 1-year rate of death or disabling stroke compared to those with normal CRP levels (16.7% vs. 5.5%, <i>P</i> = 0.009). In the multivariate Cox-proportional hazard model, an elevated level of CRP was identified as an independent predictor of 1-year death or disabling stroke (hazard ratio, 2.84; 95% confidence interval, 1.10–7.34; <i>P</i> = 0.03). After the addition of information about CRP concentration to the Society of Thoracic Surgeons (STS) score model, the C-index for the prediction of death or disabling stroke substantially increased from 0.655 to 0.710, and a continuous net reclassification improvement of 0.529 (0.054–1.004) was noted. And there was no significant relationship between the primary outcome and other biomarkers, included B-type natriuretic peptide (BNP) and troponin I, in our study. <b>Conclusions</b><b>:</b> In patients undergoing TAVR, elevated CRP levels were significantly associated with an increased risk of death or disabling stroke and also augmented event prediction, suggesting that CRP could be used as biomarker into a risk prediction model for TAVR.
DOI: 10.6084/m9.figshare.8118704
title: Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting with or without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial

description: <b>Background:</b> This study examined the impact of mitral valve repair (MVRe) on survival of patients with moderate or severe (≥2+) MR and ischemic cardiomyopathy randomized to coronary artery bypass grafting (CABG) versus CABG+surgical ventricular reconstruction (SVR) in the STICH trial. <b>Methods:</b> Among patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG or CABG+SVR, the impact of MVRe on mortality between the two treatment arms was compared. <b>Results:</b> Among 867 patients with assessment of baseline MR severity, 211 had moderate or severe MR. After excluding 7 patients who underwent mitral valve replacement, 50, 44, 62, and 48 patients underwent CABG, CABG+MVRe, CABG+SVR, and CABG+SVR+MVRe, respectively. Four-year mortality rates were lower following CABG+MVRe than CABG alone (16% vs. 55%; adjusted hazard ratio [HR] 0.30; 95% CI 0.13–0.71). In contrast, the CABG+SVR+MVRe and CABG+SVR groups had similar 4-year mortality of 39% vs. 39% (adjusted HR 0.88; 95% CI 0.46–1.70). MVRe had a more favorable effect on survival in patients undergoing CABG alone compared to CABG+SVR (<i>p</i> = 0.013). Baseline MR severity was similar between patients that received CABG+MVRe and those that underwent CABG+SVR+MVRe. A larger proportion of patients demonstrated a reduction in MR between 4 and 24 months after CABG+MVRe compared to CABG+SVR+MVRe (50.0% versus 25.0%, <i>p</i> = 0.023). <b>Conclusion:</b> In patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG, MVRe appears to have a favorable effect on survival. The addition of SVR to CABG may attenuate the anticipated benefits of MVRe by limiting the long-term reduction of MR with MVRe.
DOI: 10.6084/m9.figshare.8118704.v2
title: Differential Impact of Mitral Valve Repair on Outcome of Coronary Artery Bypass Grafting with or without Surgical Ventricular Reconstruction in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial

description: <b>Background:</b> This study examined the impact of mitral valve repair (MVRe) on survival of patients with moderate or severe (≥2+) MR and ischemic cardiomyopathy randomized to coronary artery bypass grafting (CABG) versus CABG+surgical ventricular reconstruction (SVR) in the STICH trial. <b>Methods:</b> Among patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG or CABG+SVR, the impact of MVRe on mortality between the two treatment arms was compared. <b>Results:</b> Among 867 patients with assessment of baseline MR severity, 211 had moderate or severe MR. After excluding 7 patients who underwent mitral valve replacement, 50, 44, 62, and 48 patients underwent CABG, CABG+MVRe, CABG+SVR, and CABG+SVR+MVRe, respectively. Four-year mortality rates were lower following CABG+MVRe than CABG alone (16% vs. 55%; adjusted hazard ratio [HR] 0.30; 95% CI 0.13–0.71). In contrast, the CABG+SVR+MVRe and CABG+SVR groups had similar 4-year mortality of 39% vs. 39% (adjusted HR 0.88; 95% CI 0.46–1.70). MVRe had a more favorable effect on survival in patients undergoing CABG alone compared to CABG+SVR (<i>p</i> = 0.013). Baseline MR severity was similar between patients that received CABG+MVRe and those that underwent CABG+SVR+MVRe. A larger proportion of patients demonstrated a reduction in MR between 4 and 24 months after CABG+MVRe compared to CABG+SVR+MVRe (50.0% versus 25.0%, <i>p</i> = 0.023). <b>Conclusion:</b> In patients with moderate or severe MR and ischemic cardiomyopathy undergoing CABG, MVRe appears to have a favorable effect on survival. The addition of SVR to CABG may attenuate the anticipated benefits of MVRe by limiting the long-term reduction of MR with MVRe.
DOI: 10.6084/m9.figshare.10079066.v1
title: First Reported 4D Volume Intracardiac Echocardiography Guided Left Atrial Appendage Closure in the USA

description: First Reported 4D Volume Intracardiac Echocardiography Guided Left Atrial Appendage Closure in the USA
DOI: 10.6084/m9.figshare.10079066
title: First Reported 4D Volume Intracardiac Echocardiography Guided Left Atrial Appendage Closure in the USA

description: First Reported 4D Volume Intracardiac Echocardiography Guided Left Atrial Appendage Closure in the USA
DOI: 10.6084/m9.figshare.7851203
title: Acute Ballooning of a Cardioform Septal Occluder During Percutaneous Closure of an Iatrogenic Atrial Septal Defect

description: Acute Ballooning of a Cardioform Septal Occluder During Percutaneous Closure of an Iatrogenic Atrial Septal Defect
DOI: 10.6084/m9.figshare.7851203.v1
title: Acute Ballooning of a Cardioform Septal Occluder During Percutaneous Closure of an Iatrogenic Atrial Septal Defect

description: Acute Ballooning of a Cardioform Septal Occluder During Percutaneous Closure of an Iatrogenic Atrial Septal Defect
DOI: 10.6084/m9.figshare.7951700.v2
title: Long-arm Clip for Transcatheter Edge-to-Edge Treatment of Mitral and Tricuspid Regurgitation – Ex-Vivo Beating Heart Study

description: <b>Background:</b> A longer-arm clip design for transcatheter edge-to-edge repair of mitral and tricuspid valves could be beneficial in treating complex valve pathologies. Its hemodynamic effects and usability are unknown. This study aims to assess its new design in an ex-vivo beating heart model. <b>Methods:</b> The long-arm clip was implanted in porcine left (n = 14) and right (n = 6) hearts with induced degenerative mitral regurgitation and functional tricuspid regurgitation, respectively. Hemodynamic conditions were assessed at baseline, pathology and post-treatment. Usability and grasping quality were evaluated during simulated treatment. <b>Results:</b> Mitral valve treatment significantly increased cardiac output (<i>p</i> p = 0.001) with respect to pathological conditions. Tricuspid treatment with grasping involving septal leaflet significantly increased cardiac output (posterior-septal grasping: <i>p</i> = 0.006; anterior-septal grasping: <i>p</i> = 0.04). There was no significant increase of transvalvular gradient pressure nor tissue damage. <b>Conclusion:</b> Long-arm clip treatment was feasible in porcine hearts, it effectively reduced regurgitation and did not significantly increase the transvalvular pressure gradient. <b>Abbreviations:</b> MV, mitral valve; DMR, degenerative mitral regurgitation; FTR, functional tricuspid regurgitation; TV, tricuspid valve; XTR Clip, long-arm clip; P2, posterior middle scallop of mitral valve; MRF, mitral regurgitation fraction; A-P, medial grasping of anterior and posterior leaflets; A-S, medial grasping of anterior and septal leaflets; P-S, medial grasping of posterior and septal leaflets; CO<sub>s</sub>, systemic cardiac output; CO<sub>p</sub>, pulmonary cardiac output; AoP, mean aortic pressure; PAP, mean pulmonary artery pressure; LAP, mean left atrial pressure; LAP<sub>syst</sub>, mean left atrial pressure during ventricular systole; Δp<sub>m</sub>, mean diastolic pressure gradient across mitral valve; Δp<sub>t</sub>, mean diastolic pressure gradient across tricuspid valve; APd, mid-systole mitral antero-posterior distance; CI, confidence interval